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Abstract Histone deacetylase (HDAC) inhibitors arrest hu-
man tumor cells at the G1 phase of the cell cycle and activate
the cyclin-dependent kinase inhibitor, p21WAF1=Cip1. However,
several studies have suggested the existence of a p21WAF1=Cip1-
independent molecular pathway. We report here that HDAC
inhibitors, trichostatin A (TSA) and sodium butyrate, activate
the p15INK4b gene, a member of the INK4 gene family, through
its promoter in HaCaT cells. Furthermore, we show that up-
regulation of p15INK4b by TSA is associated with cell growth
inhibition of HCT116 p21 (3/3) cells. Our ¢ndings suggest
that p15INK4b is one of the important molecular targets of
HDAC inhibitors.
1 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Cell cycle progression is regulated by proteins called cyclins
and cyclin-dependent kinases (CDKs) that associate with each
other [1]. The process of cyclin-dependent activation of CDKs
is counterbalanced by CDK inhibitors [2]. Two families of
CDK inhibitors have already been identi¢ed in mammalian
cells. One family, the CIP/KIP family, is comprised of
p21WAF1=Cip1, p27Kip1 and p57Kip2, and each member inhibits
cyclin E/A-CDK2 complexes [3]. Another family is also called
INK4 family proteins. The members of this family, designated
p15INK4b, p16INK4a, p18INK4c and p19INK4d, bind directly to
CDK4/6 and are speci¢c inhibitors of the cyclin D-dependent
kinases [4^6].
Histone deacetylase (HDAC) inhibitors have been reported
to arrest the cell cycle at the G1 or G2 phase [7] or to induce
di¡erentiation and apoptosis [8,9]. These agents also inhibit
the growth of cancer cells in animal models [10]. Clinical
applications have been started in a phase II study testing
depsipeptide, one of the HDAC inhibitors, in patients with
T-cell lymphoma [11].
We previously demonstrated that HDAC inhibitors, such as
sodium butyrate (butyrate) and trichostatin A (TSA), inhibit
cellular proliferation and induce the expression of the
p21WAF1=Cip1 gene through its promoter in a p53-independent
manner [12,13]. However, several recent reports have sug-
gested the existence of a p21WAF1=Cip1-independent pathway
of growth arrest by HDAC inhibitors [14^16]. Our results
demonstrate that HDAC inhibitors activate p15INK4b, a mem-
ber of INK4 family proteins, through its promoter in human
immortalized keratinocyte HaCaT. Furthermore, to exclude
the in£uence of p21WAF1=Cip1 on TSA-mediated cell growth
inhibition, we investigated the e¡ect of TSA on
p21WAF1=Cip1-deleted human colorectal carcinoma cell line
HCT116 p21 (3/3) cells.
2. Materials and methods
2.1. Cell culture and reagents
HaCaT cells (a kind gift from Dr. N.E. Fusenig, German Cancer
Research Center, Heidelberg, Germany) and HCT116 p21 (3/3) cells
(a kind gift from Dr. B. Vogelstein, Johns Hopkins University School
of Medicine, Baltimore, USA) were maintained in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM) with 10% fetal bovine serum and in-
cubated at 37‡C in a humidi¢ed atmosphere of 5% CO2. TSA (Wako,
Osaka, Japan) was dissolved in ethanol and sodium butyrate (Wako,
Osaka, Japan) in water.
2.2. Analysis of cell cycle progression
Unsynchronized HaCaT or HCT116 p21 (3/3) cells were exposed
to HDAC inhibitors for 24 h. HaCaT cells were treated with Triton
X-100. HCT116 p21 (3/3) cells were ¢xed in 70% ethanol and treated
with RNase. The nuclei were stained with propidium iodide before the
DNA content was measured using a Becton Dickinson FACS Calibur
(Becton Dickinson, Mountain View, CA, USA). At least 10 000 cells
were counted. The ModFit LD V2.0 software package (Becton Dick-
inson, Franklin Lakes, NJ, USA) was used to analyze the data.
2.3. Cloning of the 5P-£anking region of the human p15INK4b gene
Genome screening was performed using a human genomic leuko-
cyte library in the IPS1 phage (Mo Bi Tec, Gottingen, Germany) as
described previously [17]. The probe encoding a part of the human
p15INK4b gene was ampli¢ed by PCR based on the data in GenBank
accession no. AC000049, with the forward (5P-TAAATAGGTAA-
GAGTGCAAACAAAG-3P) and the reverse (5P-ATTGCTTCTGG-
GAAAAAGCGCCTAG-3P) primers.
2.4. Plasmid preparation
An approximately 7.8 kb fragment derived from the positive phage
DNA was subcloned into the luciferase reporter plasmid pGVB2
(Nippon Gene, Tokyo, Japan). Human p15INK4b expression vector
(pCD15) and its empty vector (pCD0) were gifts from C.W. Miller,
UCLA School of Medicine, Los Angeles, CA, USA [18]. These vec-
tors encode neomycin resistance gene.
2.5. Protein isolation and Western blot analysis
The cells were lysed by RIPA bu¡er (50 mM Tris^HCl, pH 7.5, 150
mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1%
sodium deoxycholate) for p15INK4b detection or lysis bu¡er (50 mM
Tris^HCl, pH 7.5, 0.1% SDS) for detection of the retinoblastoma gene
(RB) product. The protein extract was boiled for 5 min and loaded
onto a 12% (for p15INK4b detection) or 7% (for RB detection) poly-
acrylamide gel, electrophoresed, and transferred to a nitrocellulose
membrane. A rabbit polyclonal antibody to p15INK4b (C-20 from
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Santa Cruz Biotechnology, CA, USA) or to RB (PM-14001A from
Pharmingen, NJ, USA) was used as the primary antibody. The signal
was then developed with the enhanced chemiluminescence system
(Amersham Pharmacia Biotech, UK Limited).
2.6. RNA isolation and Northern blot analysis
Total RNA was isolated using a Sepasol RNA isolation kit (Na-
calai Tesque Inc., Kyoto, Japan), and poly(A)þ mRNA was separated
from 100 Wg of total RNA using an Oligotex1-dT306 Supers
mRNA Puri¢cation kit (Takara Bio Inc., Shiga, Japan). Exon 1 of
p15 cDNA was used as a probe. Northern blot analysis was per-
formed using standard methods [19]. The mRNA level was deter-
mined using a Fuji Image Analyzer Bas 2000 (Fujix, Tokyo, Japan).
2.7. Transient transfection and luciferase assay
HaCaT cells (5U104 cells) were seeded in 12-well plates, and 1.0 Wg
of reporter plasmid was transfected using a CellPhect transfection kit
(Amersham Pharmacia Biotech, UK). After 24 h, HDAC inhibitors
were added, and 48 h after transfection, the cells were harvested. The
luciferase activity of each cell lysate was measured using the Lucifer-
ase Reporter Plasmid System (Promega, WI, USA). The luciferase
activity was normalized for the amount of protein in each cell lysate.
Each experiment was repeated at least three times. Data were ana-
lyzed using the two-tailed Student’s t-test and di¡erences were con-
sidered signi¢cant from controls when P6 0.05.
2.8. Colony assay
HaCaT cells in a six-well plate were cultured for 1 day, and 2.0 Wg
of pCD15 or pCD0 was transfected using lipofectamine and plus
reagent (Invitrogen, CA, USA). After transfection, cells were main-
tained in DMEM with 10% fetal bovine serum for 5 days. G418
(Nacalai Tesque Inc., Kyoto, Japan) was added to the medium to a
¢nal concentration of 800 Wg ml31. Medium containing G418 was
exchanged twice a week. After 10 days, resistant colonies were scored
by the method of formalin ¢xation and crystal violet staining.
3. Results
3.1. HDAC inhibitors induce growth arrest at the G1 phase in
cell cycle progression in HaCaT cells
We ¢rst examined the e¡ect of HDAC inhibitors, TSA and
butyrate, on the proliferation of human immortalized keratin-
ocyte HaCaT cells. TSA inhibited the proliferation of HaCaT
cells in a dose-dependent manner and 180 nM TSA had a
cytostatic e¡ect (Fig. 1A). To investigate the e¡ect of TSA
on the cell cycle progression, the DNA content of the cell
nuclei was measured by £ow cytometric analysis. The treat-
ment with TSA increased the percentage in the G1 phase, and
decreased that in the S phase (Fig. 1B). Butyrate also inhib-
ited the proliferation in a dose-dependent manner, and had
cytostatic e¡ect at 2.4 mM (data not shown). The treatment
with butyrate increased the percentage of the G1 phase from
29.4% to 81.9%, and decreased the S phase from 45.2% to
6.7% (data not shown). These data demonstrate that HDAC
inhibitors arrest the cell cycle of HaCaT cells at the G1 phase.
3.2. HDAC inhibitors increase p15INK4b mRNA and protein
levels in HaCaT cells
In this study, we investigated whether HDAC inhibitors
a¡ect p15INK4b gene expression in HaCaT cells. We found
that TSA stimulates the expression of p15INK4b mRNA in a
dose-dependent manner (Fig. 2A). This data is consistent with
the result that TSA inhibited the growth of HaCaT cells in a
dose-dependent manner (Fig. 1A). The time course study in-
dicated that the p15INK4b mRNA was up-regulated 3 h after
treatment with TSA (Fig. 2B).
Next, we tried to elucidate whether the expression of
p15INK4b protein could also be induced by treatment with
TSA in HaCaT cells. We found that the treatment with
TSA stimulated the expression of p15INK4b protein in a
dose-dependent manner (Fig. 2C). The time course study
showed that the expression of p15INK4b protein was signi¢-
cantly increased 3 h after the treatment (Fig. 2D). Butyrate
also activated the expressions of p15INK4b protein and mRNA
in a dose-dependent manner (data not shown).
p15INK4b is a speci¢c inhibitor of the cyclin D-dependent
kinases, and the subsequent dephosphorylation of RB protein
causes G1 arrest [4]. Therefore, we examined whether TSA
can alter the phosphorylation status of RB protein in HaCaT
cells by Western blotting. A hyperphosphorylated form of RB
protein began to be converted into a hypophosphorylated
form from 12 h after the treatment (Fig. 2E).
Taken together, these results indicate that HDAC inhibitors
up-regulate the p15INK4b at mRNA and protein levels and,
subsequently, a hyperphosphorylated form of the RB protein
is converted into a hypophosphorylated form in HaCaT cells.
3.3. HDAC inhibitors activate the p15INK4b promoter activity in
HaCaT cells
Having demonstrated that the p15INK4b mRNA expression
is induced by HDAC inhibitors in HaCaT cells, we investi-
gated whether HDAC inhibitors activate the promoter activity
of the p15INK4b gene. We cloned and sequenced a 7.8 kb frag-
ment containing the 5P-£anking region of the human p15INK4b
gene. The 5P-£anking region of the human p15INK4b gene was
ligated to an empty luciferase reporter plasmid, pGVB2.
Fig. 1. E¡ect of TSA on the growth and cell cycle of HaCaT cells.
A: One day after inoculation of HaCaT cells, TSA at 90, 120, or
180 nM was added, and cell growth was compared with control cul-
ture with equivalent ethanol. The number of viable cells was
counted by trypan blue dye exclusion test. B: Unsynchronized cells
were incubated in the presence of either ethanol or 180 nM TSA
for 24 h, and the DNA content of the cells was determined by £ow
cytometry. Data represent means of duplicate experiments.
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Treatment with TSA activated the promoter activity of
p15INK4b in a dose-dependent manner (Fig. 3). Butyrate also
increased the p15INK4b promoter activity (data not shown).
These results indicate that HDAC inhibitors stimulate the
p15INK4b promoter activity in HaCaT cells.
3.4. Overexpression of p15INK4b inhibits cell growth in HaCaT
cells
We examined the e¡ect of p15INK4b overexpression on cell
growth of HaCaT cells by selecting for Geneticin resistance
after transfection with expression vectors encoding the
p15INK4b gene and neomycin resistance gene. The results are
expressed as percent recovery compared to the empty vector
(Fig. 4A). The recovery of antibiotic-resistant HaCaT cells
was markedly inhibited by the overexpression of p15INK4b.
Transfection with p15INK4b yielded 0% of the resistant colo-
nies seen with the control. Furthermore, we showed the ex-
pression of p15INK4b protein signi¢cantly increased 24 h after
transfection in HaCaT cells (Fig. 4B). These results demon-
strate that the overexpression of the p15INK4b gene inhibits
cell growth in HaCaT cells, and suggest that the activation
of the p15INK4b gene may contribute to the growth arrest
induced by HDAC inhibitors.
Fig. 3. Activation of p15INK4b promoter activity in HaCaT cells by
treatment with TSA. HaCaT cells were transiently transfected with
p15INK4b-luciferase fusion plasmid, and luciferase activities were
measured after incubation with medium containing various concen-
trations of TSA for 24 h. Data are shown as meansRS.D. (n=3).
*P6 0.03; **P6 0.01.
Fig. 4. E¡ect of p15INK4b overexpression on cell growth in HaCaT
cells. A: The bars represent relative recovery of cells after transfec-
tion with the empty vector (pCD0) or expression vector (pCD15)
encoding p15INK4b. The results were normalized by pCD0 at 100%.
Data are shown as means of triplicate experiments. B: After trans-
fection with pCD0 or pCD15, the exogenous expression of p15INK4b
protein was examined by Western blotting.
Fig. 2. Northern blot analysis of p15INK4b mRNA and Western blot
analysis of p15INK4b or RB protein in HaCaT cells. A,B: HaCaT
cells were treated in the presence of various concentrations of TSA
for 24 h (A), or in the presence of 180 nM TSA for the indicated
times (B), and the expression of p15INK4b mRNA was examined.
The mRNA level of p15INK4b was standardized by that of glyceral-
dehyde-3-phosphate dehydrogenase. C: HaCaT cells were treated
with various concentrations of TSA. The expression of p15INK4b
protein was examined after 24 h exposure to TSA. K-Tubulin (On-
cogene Research Product, CA, USA) was chosen as a loading con-
trol in all Western blotting. D,E: HaCaT cells were exposed to ei-
ther ethanol alone (3) or 180 nM TSA (+) for the indicated times.
The expressions of p15INK4b protein (D) and RB protein (E) were
detected.
FEBS 27804 5-11-03
T. Hitomi et al./FEBS Letters 554 (2003) 347^350 349
3.5. HDAC inhibitors inhibit the cell growth in HCT116 p21
(3/3) cells, and activate the expression of the p15INK4b
gene
We previously demonstrated that HDAC inhibitors inhibit
cellular proliferation and induce the expression of the
p21WAF1=Cip1 gene through its promoter in a p53-independent
manner [12,13]. However, several studies have recently sug-
gested the existence of a p21-independent pathway of the
G1 phase arrest induced by HDAC inhibitors [14^16]. There-
fore, to exclude the in£uences of p21WAF1=Cip1 on TSA-medi-
ated cell growth inhibition, the p21-deleted human colorectal
carcinoma cell line HCT116 p21 (3/3) was used. The treat-
ment with 120 nM TSA had a cytostatic e¡ect on the cell
growth, and caused the G1 and G2 arrest in the cell cycle
(data not shown). The treatment with TSA stimulated the
expression of p15INK4b protein in a dose- and time-dependent
manner (data not shown), and a hyperphosphorylated form of
RB protein was converted into a hypophosphorylated form
(data not shown).
4. Discussion
Our results indicate that HDAC inhibitors stimulate the
p15INK4b promoter activity and up-regulate the p15INK4b
mRNA and protein levels, and then a hyperphosphorylated
form of the RB protein is converted into a hypophosphory-
lated form in HaCaT cells. Furthermore, HDAC inhibitors
arrest the cell cycle of HaCaT cells at the G1 phase and in-
hibit cell growth. In addition, the overexpression of p15INK4b
completely suppressed the colony formation of HaCaT cells.
Taken together, our results indicate that HDAC inhibitors
activate the expression of the p15INK4b gene through its pro-
moter, and suggest that its activation may partially contribute
to growth arrest induced by HDAC inhibitors at the G1 phase
in HaCaT cells.
We previously demonstrated that HDAC inhibitors inhibit
cellular proliferation and induce the expression of the
p21WAF1=Cip1 gene through its promoter in a p53-independent
manner. Furthermore, it has been previously shown that
p21WAF1=Cip1 is involved in butyrate-mediated growth inhibi-
tion of HCT116 cells [20]. However, several studies have re-
cently suggested the existence of a p21WAF1=Cip1-independent
pathway of the G1 phase arrest induced by HDAC inhibitors
[14^16]. We demonstrated that TSA activated the expression
of the p15INK4b gene in HCT116 p21 (3/3), accompanied by
cell growth inhibition. This result suggests that the activation
of the p15INK4b gene may be important in p21WAF1=Cip1-inde-
pendent cell growth inhibition by TSA.
Inactivation of p16INK4a has been extensively reported in
most human malignant tumors [21]. As a member of the
INK4 family, p15INK4b is known to possess a function similar
to that of p16INK4a. This functional similarity to p16INK4a
suggests that p15INK4b may function as a replacement for
p16INK4a in case p16INK4a is inactivated. Therefore, transcrip-
tionally regulated agents of the p15INK4b gene may contribute
to new strategies for the prevention or therapy of malignan-
cies, which we have termed ‘gene-regulating chemoprevention
or chemotherapy’ [22,23]. In that sense, butyrate, which acti-
vates p15INK4b gene expression, would be representative of
gene-regulating chemopreventive agents. Butyrate is one of
the most abundant short chain fatty acids in the large intes-
tine generated by bacterial fermentation of dietary ¢bers [24].
Butyrate has anti-tumor properties in vivo and in vitro at
physiological concentrations, suggesting that butyrate may
have preventive e¡ects against large bowel cancer [25^27].
U. Aytac et al. [18] have recently reported an interesting
result showing that p15INK4b inhibits cell proliferation inde-
pendent of RB. Ectopic overexpression of p16INK4a can inhibit
the growth of cell lines depending on RB status. However, in
the case of p15INK4b, cell proliferation was inhibited in cells
lacking RB as well as in cells with wild-type RB expression.
Therefore it is suggested that the agents activating the
p15INK4b gene may have growth inhibitory e¡ects on a broad
spectrum of tumors regardless of RB status.
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